Well, OSCI hasn't been on the radar screen for quite a while.The one aspect that had & still interests me intellectually perhaps more than investment wise is:The company also has a late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease.Here is the Yahoo summary page for them if anyone would like to take a look.http://finance.yahoo.com/q?s=osciI might also suggest you take your questions, virtuexru, to the biotech board. Here is the link:http://boards.fool.com/Message.asp?mid=26012994Lots of very well schooled & smart friends there.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra